Bovine Functional Genomics Laboratory, Agricultural Research Service, Beltsville, MD 20705, USA.
J Dairy Sci. 2013 Mar;96(3):1793-802. doi: 10.3168/jds.2012-6216. Epub 2013 Jan 9.
Damage to the intestinal epithelium reduces nutrient absorption and animal growth, and can have negative long-term health effects on livestock. Because the intestinotropic hormone glucagon-like peptide 2 (GLP-2) has been shown to contribute to gut integrity, reduce inflammation, and improve nutrient absorption, the present study was designed to determine whether administration of GLP-2 to calves with coccidiosis in the first month of life affects intestinal growth and mediates negative effects of the proinflammatory response. Holstein bull calves (n=19) were assigned to 4 treatment groups of 4 to 5 calves each: (1) infected with Eimeria bovis, GLP-2 treated; (2) noninfected, GLP-2 treated; (3) infected with E. bovis, buffer treated; and (4) noninfected, buffer treated. Infected calves received 100,000 to 200,000 sporulated E. bovis oocysts suspended in milk replacer on d 0 of the study. On d 18, calves in the GLP-2 groups received a subcutaneous injection of 50 μg of bovine GLP-2/kg of body weight twice daily for 10 d, and calves in the buffer-treated groups received an equivalent volume of sodium bicarbonate buffer only. On d 28, calves were slaughtered 2h after injection of 5-bromo-2'-deoxyuridine (BrdU). Intestinal tissues were measured and villus height, crypt depth, and BrdU immunostaining were evaluated in segments of the small intestine. Nitrotyrosine immunostaining, a measure of nitro-oxidative damage, was evaluated in the ileum and cecum. No GLP-2 treatment by E. bovis infection interaction was observed for any parameter measured, with the exception of nitrotyrosine immunostaining in the cecum. Large intestinal weight was greater in infected than noninfected calves and with GLP-2 treatment relative to buffer treatment. Calves that received GLP-2 also had greater small intestinal weight but no difference in cell proliferation, as assessed by BrdU labeling, relative to buffer-treated calves. No treatment effects were detected for villus height, crypt depth, or villus height:crypt depth ratio in segments of the small intestine. Protein tyrosine nitration was over 3-fold greater in the ileum and cecum of infected calves relative to noninfected calves, and GLP-2 therapy reduced tyrosine nitration in infected calves by 47% in the ileum and 69% in the cecum relative to buffer-treated calves. Treatment with GLP-2 promotes intestinal growth in neonatal calves and reduces the detrimental effects of nitro-oxidative stress in the ileocecum of calves with coccidiosis.
肠上皮损伤会减少营养吸收和动物生长,并对牲畜的长期健康产生负面影响。由于肠促胰岛素激素胰高血糖素样肽 2 (GLP-2) 已被证明有助于肠道完整性、减少炎症和改善营养吸收,因此本研究旨在确定在生命的第一个月给患有球虫病的小牛施用 GLP-2 是否会影响肠道生长并介导促炎反应的负面影响。荷斯坦公牛小牛(n=19)被分配到 4 个处理组,每组 4-5 头小牛:(1)感染牛艾美球虫,GLP-2 处理;(2)未感染,GLP-2 处理;(3)感染,缓冲液处理;和(4)未感染,缓冲液处理。感染的小牛在研究的第 0 天接受 100,000 至 200,000 个孢子化的牛艾美球虫卵囊悬浮在代乳中。在第 18 天,GLP-2 组的小牛每天两次皮下注射 50 μg 牛 GLP-2/kg 体重,持续 10 天,缓冲液处理组的小牛仅接受等量的碳酸氢钠缓冲液。在第 28 天,注射 5-溴-2'-脱氧尿苷(BrdU)后 2 小时屠宰小牛。测量肠道组织,并评估小肠段的绒毛高度、隐窝深度和 BrdU 免疫染色。在回肠和盲肠中评估硝基酪氨酸免疫染色,这是一种衡量硝基氧化损伤的指标。除了盲肠中的硝基酪氨酸免疫染色外,未观察到 GLP-2 处理与 E. bovis 感染之间存在任何测量参数的相互作用。与缓冲液处理相比,感染的小牛的大肠重量更大,并且 GLP-2 处理也更大。与缓冲液处理的小牛相比,接受 GLP-2 的小牛的小肠重量也更大,但 BrdU 标记评估的细胞增殖没有差异。在小肠段的各个部位,绒毛高度、隐窝深度或绒毛高度:隐窝深度比均未检测到治疗效果。感染小牛的回肠和盲肠中的蛋白酪氨酸硝化作用比非感染小牛高出 3 倍以上,GLP-2 治疗使感染小牛的回肠和盲肠中的酪氨酸硝化作用分别降低了 47%和 69%,与缓冲液处理的小牛相比。GLP-2 的治疗促进了新生小牛的肠道生长,并降低了患有球虫病的小牛回肠和盲肠中硝基氧化应激的有害影响。